The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
The inclusion of broad-spectrum sunscreen in the WHO EML and EMLc follows an application submitted in November 2024 by the Global Albinism Alliance
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
Relmada expects to initiate its Phase 3 program in the first half of 2026
Venus Remedies now has 29 active product approvals in Vietnam alone
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Subscribe To Our Newsletter & Stay Updated
